# US 2025/0136559 A1 · Smo modulator compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0136559 A1
- Document ID: US20250136559A1
- Status: Published application
- Kind: A1
- Application number: 18/834,797
- Filed: 2023-02-01
- Published: 2025-05-01
- Earliest claimed: 2022-02-01
- Applicants: Omass Therapeutics Limited
- Inventors: Giles Albert Brown; Laia Malet Sanz; Benjamin Tehan; Omprakash Bande
- Web page: https://patentgrep.com/patent/US20250136559A1

## CPC

- C07D 249/08: 1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D 295/073: with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- A61K 31/541: Non-condensed thiazines containing further heterocyclic rings
- A61P 35/00: Antineoplastic agents
- C07D 231/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 261/08: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 263/32: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 271/06: 1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C07D 271/113: with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D 295/092: with aromatic radicals attached to the chain
- C07D 295/112: with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 401/14: containing three or more hetero rings
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 409/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The disclosures herein relate to novel compounds of Formula (1a) or a salt thereof, wherein X1, X2, X3, X4, Y1, Y2, Y3, Y4, Z1, Z2, Z3, Z4, W, R1, R4, R5, R6 and R7 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with SMO receptors.

## Claims

### Claim 1

A compound of Formula (1a):
or a salt thereof, wherein;
W is S, SO or SO2;
X1, X2, X3 and X4 are N, CH or CR2, where one or none of X1, X2, X3 and X4 are N and one or none of X1, X2, X3 and X4 are CR2;
Y1, Y2, Y3 and Y4 are N, CH or CR3, where one or none of Y1, Y2, Y3 and Y4 are N and one or none of Y1, Y2, Y3 and Y4 are CR3;
Z1 is C or N;
Z2 is O, N, NR8, CR8 or S;
Z3 is O, N, NR9, CR9 or S;
Z4 is O, N, NR10, CR10 or S;
R1 is H or methyl;
R2 is H, CN, halo, C1-3 alkyl optionally substituted with 1-3 fluorine atoms or C1-3 alkoxy optionally substituted with 1-3 fluorine atoms;
R3 is H, halo or methyl;
R4 is H, halo, NR11R12, a group —(CH2)nR13, where n is 0-3, or linear or branched C1-6 alkyl optionally substituted with 1-3 fluorine atoms;
R5, R6 and R7 are independently H or C1-3 alkyl optionally substituted with 1-3 fluorine atoms;
R8, R9 and R10 are independently H or C1-3 alkyl optionally substituted with 1-3 fluorine atoms;
R11 and R12 are independently H or C1-3 alkyl;
R13 is optionally substituted C3-6 cycloalkyl, optionally substituted phenyl or an optionally substituted 5- or 6-membered heterocyclic ring;
wherein, when
is:
is
X1, X2, X3, X4, Y1, Y2, Y3 and Y4 are not all CH, or R1 and R5 are not both H.

### Claim 2 (depends on 1)

The compound according to claim 1, which is a compound of formula (2a):
or a salt thereof.

### Claim 3 (depends on 1)

The compound according to claim 1, which is a compound of formula (3a), (3b) or (3c):
or a salt thereof.

### Claim 4 (depends on 1)

The compound according to claim 1, wherein the moiety:
is selected from:

### Claim 5 (depends on 1)

The compound according to claim 1, which is a compound of Formula (4a), (4b) or (4c):
or a salt thereof.

### Claim 6 (depends on 1)

The compound according to claim 1, wherein the moiety:
is selected from:

### Claim 7 (depends on 1)

The compound according to claim 1, wherein R8, R9 and R10 are independently H or methyl.

### Claim 8 (depends on 1)

The compound according to claim 1, wherein R4 is H, halo, NR11R12, a group —(CH2)nR13, where n is 0-3, or linear or branched C1-6 alkyl optionally substituted with 1-3 fluorine atoms;
R13 is C3-6 cycloalkyl, phenyl optionally substituted with one or more R14 groups, a 5- or 6-membered heterocyclic group optionally substituted with one or more R14 groups, a 1,4-benzodioxane ring system optionally substituted with one or more R14 groups, or a 1,3 benzodioxole ring system optionally substituted with one or more R14 groups;
wherein R14 is halo, C1-3 alkyl optionally substituted with 1-3 fluorine atoms, C1-3 alkoxy optionally substituted with 1-3 fluorine atoms, or a group —(CH2)m(O)pR15;
where R15 is phenyl optionally substituted with 1-3 fluorine atoms or thiazole;
m is 0-3; and
p is 0 or 1.

### Claim 9 (depends on 1)

The compound according to claim 1, wherein R4 is selected from:

### Claim 10

(canceled)

### Claim 11 (depends on 1)

The compound according to claim 1, wherein the moiety:
is selected from:

### Claim 12

(canceled)

### Claim 13 (depends on 1)

The compound according to claim 1, which is a compound of Formula (5a), (5b), (5c), (5d) or (5e):
or a salt thereof.

### Claim 14 (depends on 1)

The compound according to claim 1, wherein R1 is H.

### Claim 15 (depends on 1)

The compound according to claim 1, wherein R2 is H, methyl, Cl, F, methoxy, trifluoromethyl or CN.

### Claim 16

(canceled)

### Claim 17 (depends on 1)

The compound according to claim 1, wherein R3 is H, methyl or F.

### Claim 18

(canceled)

### Claim 19 (depends on 1)

The compound according to claim 1, wherein R5 is H or methyl.

### Claim 20

(canceled)

### Claim 21 (depends on 1)

The compound according to claim 1, which is selected from the group consisting of:

### Claim 22 (depends on 1)

A pharmaceutical composition comprising a compound as defined in claim 1 and a pharmaceutically acceptable excipient.

### Claim 23 (depends on 1)

The compound according to claim 1 for use in medicine.

### Claim 24 (depends on 1)

A method of treating cancer, comprising administering a compound according to claim 1 to a patient in need thereof.

### Claim 25 (depends on 24)

The method according to claim 24, wherein the cancer is colorectal cancer, pancreatic cancer, breast cancer, prostate cancer, esophageal cancer, gastric cancer, blood cancer, lung cancer, brain cancer, medulloblastic cancer, skin cancer, basal cell carcinoma, head and neck cancer, ovarian cancer, bladder cancer, kidney cancer, lung cancer, breast cancer, pancreatic cancer or stomach cancer.
